Referências Bibliográficas:
1. Coelho LGV, Marinho JR, Genta R, Ribeiro LT, Passos MCF, Zaterka MCF, et al. IV Consenso brasileiro sobre Helicobacter pylori. Arq Gastroenterol. 2018;55(2):97–121.
2. Lages RB. V Consenso brasileiro sobre Helicobacter pylori: o que há de novo? Gastropedia 2025, Vol II [acesso em 17 dez 2025]. Disponível em: https://gastropedia.pub/pt/gastroenterologia/v-consenso-brasil eiro-sobre-helicobacter-pylori-o-queha-de-novo/.
3. Correa P. The epidemiology of gastric cancer. World J Surg. 1991;15(2):228-34.
4. Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019;14(1):26-38.
5. Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353-67.
6. Capelle C, Vries AC, Haringsma J, Borg FT, Vries RA, Bruno MJ, et al. OLGIM staging for intestinal metaplasia as an alternative to OLGA. Gut 2010;59(6):774-9.
7. Benites-Goñi, Cabrera-Hinojosa D, Latorre G, Hernandez AV, Uchima H, Riquelme A. The OLGA and OLGIM systems for risk stratification of gastric cancer: a systematic review and meta-analysis. Therap Adv Gastroenterol. 2025:18:17562848251325461.
8. Smyth C, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D.Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v38-v49.
9. Ajani JA, D’Amico TA, Bentrem DJ, Corvera CU, Das P, Enzinger PC, et al. Gastric cancer, version 2.2025, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2025;23(5):169-91.
10. van der Post RS, Vogelaar IP, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015 ;52(6):361-74.
11. Blair V, McLeod M, Carneiro F, Coit DG, D’Addario JL, van Dieren JM, et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol. 2020;21(8):e386-e397.
12. Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, et al; US Multi-Society Task Force on ColorectalCancer. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastroenterology, 2014;147(2):502-26.
13. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, liver flukes and Helicobacter pylori: views and expert opinions of an IARC Working Group on the evaluation of carcinogenic risks to humans. Lyon: IARC Working Group; 1994.
14. Yao K. The endoscopic diagnosis of early gastric cancer. Ann Gastroenterol. 2013;26(1):11-22.
15. Yao K, Uedo N, Kamada T, Hirasawa T, Nagahama T, Yoshinaga S, et al. Guidelines for endoscopic diagnosis of early gastric cancer. Dig Endosc. 2020;32(5):663-98.
16. Hisada H, Sakaguchi Y, Oshio K, Mizutani S, Nakagawa H, Sato, J, et al. Endoscopic treatment of superficial gastric cancer: present status and future.Cur r Oncol. 2022;29(7):4678-88.
17. Muto M, Yao K, Kaise M, Kato M, Uedo N, Yagi K, et al. Magnifying endoscopy simple diagnostic algorithm for early gastric cancer (MESDA-G). D ig Endosc. 2016;28(4):379-93.
18. Sociedade Brasileira De Oncologia Clínica (SBOC). Diretrizes de tratamento oncológico SBOC 2025: estômago – doença localizada. São Paulo: SBOC, 2025.
19. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer. Version 2.2026. Plymouth Meeting (PA): NCCN; 2026. Jan 21, 2026 [Acesso em: 04 de março de 2026].
20. Ono H, Yao K, Fujishiro M, Oda I, Uedo N, Nimura S, et al. Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer (second edition). Dig Endosc. 2021;33(1):4-20.
21. Chiarello MM, Fico V, Pepe G, Tropeano G, Adams NJ, Altieri G, et al. Early gastric cancer: a challenge in Western countries. World J Gastroenterol. 2022;28(7):693-703.
22. Souza WP, Pereira MA, Cardili L, Zilberstein B, Ribeiro‑Junior U, Ramos MFKP. Evaluation of the endoscopiccure criteria in patients undergoing surgery for early gastric cancer. J Surg Oncol. 2024;130(4):743-9.
23. Hatta W, Gotoda T, Koike T, Masamune A. History and future perspectives in Japanese guidelines for endoscopic resection of early gastric cancer. Dig Endosc. 2020;32(2):180-90.
24. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2023 (6th edition). Gastric Cancer. 2023;26(1):1-25.
25. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49.
26. Instituto Nacional De Câncer (INCA). Estimativa 2023: incidência de câncer no Brasil. Rio de Janeiro: INCA; 2022.
27. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van De Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New Engl J Med. 2006;355(1):11-20.
28. Al‑Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapywith flu orouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro‑esophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948-57.
29. Hoeppner J, Brunner T, Lordick F, Schmoor C, Kulemann B, Neumann UP, et al. Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial). BMC Cancer. 2016:16:503.
30. Ychou M, Boige V, Pignon J-P, Conroy T, Bouché O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715-21.
31. Noh SH, Park SR, Yang H-K, Chung HC, Chung I-J, Kim S-W, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5‑year follow‑up of an open‑label, randomized phase 3 trial. Lancet Oncol. 2014;15(12):1389-96.
32. Agência Nacional de Vigilância Sanitária – Anvisa. Imfinzi (durvalumabe). Brasília: Ministério da Saúde; 23 fev 2026 [citado em 10 mar 2026]. Disponível em: https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/novos-medicamentos-e-indicacoes/imfinzi-durvalumabe . Acesso em 10/03/2026.
33. Janjigian Y, Al‑Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med. 2025;393(3):217-30.
34. Kim I-H, Kang SJ, Choi W, Seo AN, Eom BW, Kang B, et al. Korean Practice Guidelines for Gastric Cancer 2024: an evidence-based, multidisciplinary approach (update of 2022 Guideline). J Gastric Cancer. 2025;25(1):5-114.
35. Degiuli O, Sasako M, Ponti A, Vendrame A, Tomatis M, Mazza C, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg. 2014;101(2):23-31.
36. Kurokawa Y, Doki Y, Mizusawa J, Yoshikawa T, Yamada T, Kimura Y, et al. Five-year follow-up of a randomized clinical trial comparing bursectomy and omentectomy alone for resectable gastric cancer (JCOG1001). Br J Surg. 2022;110(1):50-6.
37. Son S-Y, Hur H, Hyung WJ, Park Y-K, Lee H-J, An JY, et al. Laparoscopic distal gastrectomy versus open distal gastrectomy for locally advanced gastric cancer: KLASS-02 randomized clinical trial. JAMA Surg. 2022;157(10):879-86.
38. Guerrini GP, Esposito G, Magistri P, Serra V, Guidetti C, Olivieri T, et al. Robotic versus laparoscopic gastrectomy for gastric cancer: the largest meta-analysis. Int J Surg. 2020:82:210-228.
39. Siewert Jr, Stein HJ. Classification of adenocarcinoma of the esophagogastric junction. Br J Surg. 1998;85(11):1457-9.
40. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand. 1965:64:31-49.
41. Tsuji T, Isobe T, Seto Y, Tanaka C, Kojima K, Motoori M, et al. Effects of creating a jejunal pouch on postoperative quality of life after total gastrectomy: a cross-sectional study. Ann Gastroenterol Surg. 2021;6(1):63-74.
42. Ilhan E, Okut G. Double tract reconstruction in proximal gastric tumors: a systematic review of clinical and functional outcomes. World J Gastrointest Surg. 2025;17(9):109030.
43. Weimann A, Braga M, Carli F, Higashiguchi T, Hübner M, Klek S, et al. ESPEN guideline: clinical nutrition in surgery. Clin Nutr.2017;36(3):623-50.
44. Aguilar‑Nascimento JE, Bicudo‑Salomao A, Caporossi C, Silva RM, Cardoso EA, Santos TP. Acerto pós-operatório: avaliação dos resultados da implantação de um protocolo multidisciplinar de cuidados perioperatórios em cirurgia geral. Rev Col Bras Cir. 2006;33(3):181-8.
45. Aguilar-Nascimento JE, Bicudo-Salomão A, Caporossi C, Silva RM, Cardoso EA, Santos TP. Enhancing surgical recovery in Central-West Brazil: The ACERTO protocol results. E Spen Eur E J Clin Nutr Metab. 2008;3(2):e78-e83.
46. Bicudo-Salomão A, Meireles MB, Caporossi C, Crotti PL, de Aguilar-Nascimento JE. Impact of the ACERTO project in the postoperative morbi-mortality in a university hospital. Rev Col Bras Cir. 2011;38(1):3-10.
47. Compton CC, Robb JA, Anderson MW, Berry AB, Birdsong GG, Bloom KJ, et al. Preanalytics and precision pathology: pathology practices to ensure molecular integrity of cancer patient biospecimens for precision medicine. Arch Pathol Lab Med. 2019;143(11):1346-63.
48. Assis E. Manual de boas práticas em patologia. São Paulo: Sociedade Brasileira de Patologia: Livromed Paulista Eireli; 2021.
49. Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182-8.
50. American Joint Committee on Cancer – AJCC. Cancer staging manual. 8. ed. Cham: Springer; 2017.
51. Oncology Nursing Society Position. Role of the oncology nurse navigator throughout the cancer trajectory. Oncol Nurs Forum.2018;45(3):283.
52. Ministério da Saúde – BRASIL. Protocolos clínicos e diretrizes terapêuticas em oncologia. Brasília: Ministério da Saúde, 2014.
53. Chen M, Wu VS, Falk D, Cheatham C, Cullen J, Hoehn R. Patient Navigation in Cancer Treatment: A Systematic Review. Curr Oncol Rep. 2024 May;26(5):504-537. doi: 10.1007/s11912-024-01514-9. Epub 2024 Apr 6. PMID: 38581470; PMCID: PMC11063100.
54. Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: diagnosis, staging and treatment. Ann Oncol. 2022;33(10):1005-20.
55. Freeman HP. The origin, evolution, and principles of patient navigation. Cancer Epidemiol Biomarkers Prev. 2012;21(10):1614-7.
56. Freeman HP. The history, principles, and future of patient navigation: commentary. Semin Oncol Nurs. 2013;29(2):72-5.
57. Instituto Nacional De Câncer (INCA). Diretrizes para o diagnóstico e tratamento do câncer de estômago. Rio de Janeiro: INCA, 2025.
58. Cheville AL, Alberts SR, Rummans TA, Basford JR, Lapid MI, Sloan JA, et al. Improving adherence to cancer treatment by addressing quality of life in patients with advanced gastrointestinal cancers. J Pain Symptom Manage. 2015;50(3):321-7.
59. Ajani JA, D’Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al Gastric cancer: clinical practice guidelines in oncology.Version 2.2022. J Natl Compr Canc Netw. 2022;20(2):167-92.
60. Shan B, Shan L, Morris D, Golani S, Saxena A. Systematic review on quality of life outcomes after gastrectomy for gastric carcinoma. J Gastrointest Oncol. 2015;6(5):544-60.
61. Barchi LC, Ramos MFKP, Dias AR, Andreollo NA, Weston AC, Lourenço LG, et al. Consenso Brasileiro de Câncer Gástrico realizado pela Sociedade Brasileira de câncer gástrico. ABCD Arq Bras Cir Dig 2023;33(2):e1514.
62. McMullen L. Oncology nurse navigators and the continuum of cancer care.Semin Oncol Nurs. 2013;29(2):105-17.
63. Duarte RMA, Fortes RC. Atuação do enfermeiro como agente educador de pacientes oncológicos em tratamento quimioterápico: Uma revisão integrativa. Braz J Develop. 2022;8(1):4332-50.
64. BRASIL. Lei nº 13.896, de 30 de outubro de 2019. Altera a Lei nº 12.732/2012 para assegurar a realização de exames diagnósticos de câncer no prazo máximo de 30 dias. Diário Oficial da União, Brasília, DF, 31 out. 2019.
65. BRASIL. Lei nº 12.732, de 22 de novembro de 2012. Dispõe sobre o primeiro tratamento de paciente com neoplasia maligna comprovada e estabelece prazo para seu início. Diário Oficial da União, Brasília, DF, 23 nov. 2012.
66. Freeman HP, Rodriguez RL. History and principles of patient navigation. Cancer. 2011;117(15 suppl.):3539–42.
67. Wells KJ, Battaglia TA, Dudley DJ, Garcia R, Greene A, Calhoun E, et al. Patient navigation: state of the art or is it science? Cancer. 2008;113(8):1999–2010.
68. Paskett ED, Harrop JP, Wells KJ. Patient navigation: an update on the state of the science. CA Cancer J Clin. 2011;61(4):237–49.
69. Bush ML, Kaufman MR, Shackleford T. Adherence in the Cancer Care Setting: a Systematic Review of Patient Navigation to Traverse Barriers. J Cancer Educ. 2018 Dec;33(6):1222-1229. doi: 10.1007/s13187-017-1235-2. PMID: 28567667; PMCID: PMC5711635.
70. Freund KM, Battaglia TA, Calhoun E, Dudley DJ, Fiscella K, Paskett E, et al. The National Cancer Institute Patient Navigation Research Program: methods, protocol, and measures. Cancer. 2014;120(2):191–200.
71. Wells KJ, Battaglia TA, Dudley DJ, Garcia R, Greene A, Calhoun E, Mandelblatt JS, Paskett ED, Raich PC; Patient Navigation Research Program. Patient navigation: state of the art or is it science? Cancer. 2008 Oct 15;113(8):1999-2010. doi: 10.1002/cncr.23815. PMID: 18780320; PMCID: PMC2679696.
72. Aguilar‑Nascimento JE, Bicudo‑Salomão A, Waitzberg DL, Dock‑Nascimento DB, Corrêa MITD, Campos ACL, et al. ACERTO guidelines of perioperative nutritional interventions in elective general surgery. Rev Col Bras Cir. 2017;44(06):633-48.
73. Arends J, Baracos V, Bertz H, BozzettiF, Cald e PC, Deutz NEP, et al. ESPEN expert group recommendations for action against cancer‑related malnutrition. Clin Nutr. 2017a;36:1187-96.
74. Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017b;36(1):11-48.
75. August DA, Huhmann MB, American Society for Parenteral and Enteral Nutrition (ASPEN) Board of Directors. A.S.P.E.N. clinical guidelines: nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation. JPEN J Parenter Enteral Nutr. 2009;33(5):472-500.
76. Bauer J, Capra S, Ferguson M. Use of the scored Patient‑Generated Subjective Global Assessment (PG‑SGA) as a nutrition assessment tool in patients with cancer. Eur J Clin Nutr. 2002;56(8):779-85.
77. Baldwin C, Spiro A, Ahern R, Emery PW. Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta‑analysis. J Natl Cancer Inst. 2012;104(5):371-85.
78. Bischoff SC, Austin P, Boeykens K, Chourdakis, M, Cuerda C, Jonkers‑Schuitema C, et al. ESPEN guideline on home enteral nutrition. Clin Nutr. 2020;39:5-22.
79. Boléo‑Tomé C, Monteiro‑Grillo I, Camilo M, Ravasco P. Validation of the Malnutrition Universal Screening Tool (MUST) in cancer. Br J Nutr. 2012;108(2):343-8.
80. Bozzetti F,Santarpia L, Pironi L, Thul P, Klek S, Gavazzi C, et al. The prognosis of incurable cachectic cancer patients on home parenteral nutrition: a multicentre observational study with prospective follow‑up of 414 patients. Ann Oncol. 2014;25(2):487-93.
81. Bowrey DJ, Baker M, Halliday V, Thomas AL, Pulikottil‑Jacob R, Smith K, et al. A randomised controlled trial of six weeks of home enteral nutrition versus standard care after oesophagectomy or total gastrectomy for cancer: report on a pilot and feasibility study. Trials. 2015:16:531.
82. Braga M, Ljungqvist O, Soeters P, Fearon K, Weimann A, Bozzetti F. ESPEN guidelines on parenteral nutrition: surgery. Clin Nutr. 2009;28(4):378-86.
83. Braga M, Wischmeyer PE, Drover J, Heyland DK. Clinical evidence for pharmaconutrition in major elective surgery. JPEN J Parenter Enteral Nutr. 2013;37(5 Suppl):66S-72S.
84. Chantragawee C, Achariyapota V. Utilization of a scored patient‑generated subjective global assessment in detecting a malnourished status in gynecologic cancer patients. Asian Pac J Cancer Prev. 2016;17(9):4401-4.
85. Chow R, Bruera E, Chiu L, Chow S, Chiu N, Lam H, et al. Enteral and parenteral nutrition in cancer patients: a systematic review and meta‑analysis. Ann Palliat Med. 2016;5(1):30-41.
86. Deslandes SF. Análise do discurso oficial sobre a humanização da assistência hospitalar. Cienc Sau Col. 2004;9(1):7-14.
87. De Pinho N, Martucci R, Rodrigues V, D’almeida CA, Thuler LCS, Saunders C, et al. Malnutrition associated with nutrition impact symptoms and localization of the disease: results of a multicentric research on oncological nutrition. Clin Nutr. 2019;38(3):1274-9.
88. De Pinho N, Martucci R, Rodrigues V, D’almeida CA, Thuler LCS, Saunders C, et al. High prevalence of malnutrition and nutrition impact symptoms in older patients with cancer: results of a Brazilian multicenter study. Cancer. 2020;126(1):156-64.
89. Sociedade Brasileira de Nutrição Oncológica – SBNO. I Consenso brasileiro de nutrição oncológica da SBNO. Rio de Janeiro: Edite; 2021.
90. Drover JW, Dhaliwal R, Weitzel L, Wischmeyer PE, Ochoa JB, Heyland DK. Perioperative use of arginine‑supplemented diets: a systematic review of the evidence. J Am Col Surg. 2011;212:385-99.
91. Dubhashi SP, Kayal A. Preoperative nutritional assessment in elderly cancer patients undergoing elective surgery: MNA or PG‑SGA? Indian J Surg. 2015;77(Suppl 2):232-5.
92. Faramarzi E, Mahdavi R, Mohammad‑Zadeh M, Nasirimotlagh B. Validation of nutritional risk index method against Patient‑Generated Subjective Global Assessment in screening malnutrition in colorectal cancer patients. Chin J Cancer Res. 2013;25(5):544-8.
93. Gavazzi C, Colatruglio S, Valoriani F, Mazzaferro V, Sabbatini A, Biffi R, et al. Impact of home enteral nutrition in malnourished patients with upper gastrointestinal cancer: a
multicentre randomised clinical trial. Eur J Cancer. 2016:64:107-12.
94. Gianotti L, Braga M, Nespoli L, Radaelli G, Beneduce A, Di Carlo VA. Randomized controlled trial of preoperative oral supplementation with a specialized diet in patients with gastrointestinal cancer. Gastroenterology. 2002;122(7):1763-70.
95. Guerra RS, Sousa AS, Fonseca I, Pichel F, Resto MT, Ferreira S, et al. Análise comparativa do rastreamento de desnutrição e ferramentas diagnósticas como preditores de custos de internação. J Hum Nutr Diet. 2016;29(2):165-73.
96. Guerra RS, Fonseca I, Sousa AS, Jesus A, Pichel F, Amaral TF. ESPEN diagnostic criteria for malnutrition – a validation study in hospitalized patients. Clin Nutr. 2017;36(5):1326-32.
97. Horie LM, Barrure APN, Castro MG, Livieira AMB, Carvalho AMB, Pereira A, et al. Diretriz BRASPEN de terapia nutricional no paciente com câncer.
BRASPEN J. 2019;34:2-32.
98. Hamza N, Darwish A, O’reilly DA, Denton J, Sheen AJ, Chang D, et al. Perioperative enteral immunonutrition modulates systemic and mucosal immunity and the inflammatory response inpatients with periampullary cancer scheduled for pancreaticoduodenectomy: a randomized clinical trial. Pancreas. 2015;44(1):41-52.
99. Heidegger CP, Berger MM , Graf S, Zingg W, Darmon P, Costanza MC, et al. Optimisation
of energy provision with supplemental parenteral nutrition in critically ill patients: a randomised controlled clinical trial. Lancet. 2013;381(9864):385-93.
100. Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). Inquérito Brasileiro de Nutrição Oncológica. Rio de Janeiro: INCA; 2013.
101. Jack BW, Chetty VK, Anthony D, Greenwald JL, Sanchez GM, Johnson AE, et al. Reengineered hospital discharge program to decrease rehospitalization. Ann Intern Med. 2009;150(3):178-87.
102. Kassin MT, Owen RM, Perez SD, Leeds I, Cox JC, Schnier K, et al. Risk factors for 30‑day hospital readmission among general surgery patients. J Am Coll Surg.
2012;215(3):322-30.
103. Lassen K, Soop M, Nygren J, Cox PBW, Hendry PO, Spies C, et al. Consensus review of optimal perioperative care in colorectal surgery: Enhanced Recovery After Surgery (ERAS) group
recommendations. Arch Surg. 2009;144(10):961-9.
104. Caro MMM, Candela CG, Rabaneda RC, Nogueira TL, Huerta MG, Kohen VL, et al. Nutritional risk evaluation and establishment of nutritional support in oncology patients according to the protocol of the Spanish Nutrition and Cancer Group. Nutr Hosp. 2008;23(5):458-68.
105. Mennuni M, Gulizia MM, Alunni G, Amico AF, Bovenzi M, Caporale R, et al. Position paper: hospital discharge planning – recommendations and standards. Eur Heart J Suppl. 2017;19(Suppl D):D244-55.
106. Osland E, Hossain MB, Khan S, Memon MA. Effect of timing of pharmaconutrition (immunonutrition) administration on outcomes of elective surgery for gastrointestinal malignancies: a systematic review and meta‑analysis. JPEN J Parenter Enteral Nutr. 2014;38(1):53-69.
107. Ottery FD. Definition of standardized nutritional assessment and interventional pathways in oncology. Nutrition. 1996;12(1 Suppl):S15-9.
108. Ravasco P, Monteiro‑Grillo I, Vidal PM, Camilo ME. Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncol. 2005a;23(7):1431-8.
109. Ravasco P, Monteiro‑Grillo I, Vidal PM, Camilo ME. Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. Head Neck. 2005b;27(8):659-68.
110. Ravasco P. Nutritional approaches in cancer: relevance of individualized counseling and supplementation. Nutrition.2015;31(4):603-4.
111. Rowan NR, Johnson JT, Fratangelo CE, Smith BK, Kemerer PA, Ferris RL. Utility of a perioperative nutritional intervention on postoperative outcomes in high‑risk head & neck cancer patients. Oral
Oncol. 2016:54:42-6.
112. Sommariva S, Pongiglione B, Tarricone R. Impact of chemotherapy‑induced nausea and vomiting on health‑related quality of life and resource utilization: a systematic review. Crit Rev Oncol Hematol. 2016:99:13-36.
113. Spotten L, Corish C, Lorton C, Dhuibhir P, O’donoghue N, O’connor B, et al. Subjective taste and smell changes in treatment‑naïve people with solid tumours. Support Care Cancer. 2016;24(7):3201-8.
114. Sealy MJ, Nijholt W, Stuiver MM, Van Der Berg MM, Roodenburg JL, Van Der Schans, et al. Content validity across methods of malnutrition assessment in patients with cancer is limited. J Clin Epidemiol. 2016:76:125-36.
115. Ortiz J, Nogueira JAM, Mateos AGL. Protein‑energy malnutrition (PEM) in cancer patients. Clin Transl Oncol. 2008;10(9):579-82.
116. Schimith MD, Lima MADS. Acolhimento e vínculo em uma equipe do Programa Saúde da Família. Cad Saúde Púb. 2004;20(6):487-1494.
117. Sriram K, Sulo S, Vanderbosch G, Partridge J, Feldstein J, Hegazi RA, et al. A comprehensive nutrition‑focused quality improvement program reduces 30‑day readmissions and length of stay in hospitalized patients. J Parent Ent Nut. 2017;41:384-91.
118. Van Aanholt DPJ, Matsuba CST, Dias MCG, Silva MLT, Campos ACL, Aguilar‑Nascimento JE. Diretriz brasileira de terapia nutricional domiciliar. BRASPEN J. 2018;33:37–46.
119. Waitzberg DL, De Aguilar-Nascimento JE, Dias MCG, Pinho N, Moura R, Correia MITD. Desnutrición y terapia nutricional en hospitales y en domicilios en Brasil: estrategias para aliviarlo – posicionamiento. Nutr Hosp. 2017;34(4):969-75.
120. Waitzberg DL, Caiaffa WT, Correia MI. Hospital malnutrition: the Brazilian national survey (IBRANUTRI): a study of 4000 patients. Nutrition. 2001;17(7-8):573-80
